Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Rating of “Moderate Buy” from Analysts

Posted by George Bondi on May 29th, 2026

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $58.8333.

A number of research analysts have recently issued reports on RAPP shares. Wells Fargo & Company lifted their price target on Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday, March 11th. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, March 10th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Tuesday, April 21st. Finally, Raymond James Financial began coverage on Rapport Therapeutics in a research note on Friday, April 10th. They set a “strong-buy” rating and a $66.00 target price on the stock.

Get Our Latest Report on Rapport Therapeutics

Rapport Therapeutics Trading Down 0.1%

Shares of NASDAQ:RAPP opened at $39.49 on Friday. Rapport Therapeutics has a 12-month low of $7.73 and a 12-month high of $42.27. The business’s fifty day simple moving average is $34.60 and its 200-day simple moving average is $30.51. The company has a market capitalization of $1.89 billion, a PE ratio of -15.19 and a beta of 0.82.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.14. The company had revenue of $20.00 million during the quarter, compared to analysts’ expectations of $7.50 million. Research analysts predict that Rapport Therapeutics will post -3.08 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Rock Ventures V. L.P. Third sold 426,005 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $40.32, for a total transaction of $17,176,521.60. Following the transaction, the insider directly owned 6,709,228 shares in the company, valued at $270,516,072.96. The trade was a 5.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Cheryl Gault sold 2,014 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total value of $58,265.02. Following the transaction, the chief operating officer owned 169,914 shares in the company, valued at approximately $4,915,612.02. This trade represents a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 897,172 shares of company stock worth $35,967,206 in the last ninety days. 13.57% of the stock is owned by insiders.

Institutional Trading of Rapport Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV acquired a new stake in Rapport Therapeutics during the 1st quarter worth about $30,000. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics during the 4th quarter worth about $37,000. Russell Investments Group Ltd. acquired a new stake in Rapport Therapeutics during the 3rd quarter worth about $43,000. Strs Ohio lifted its position in Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after acquiring an additional 400 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares during the period.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.